Gene By Gene LTD

Gene By Gene LTD was paid $9.22M by Medicaid between Apr 2020 and Dec 2024, across 6 billing codes. Its largest line is U0004, 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r — 74% of everything it billed.

33Billing provider infoGENE BY GENE LTD
HOUSTON, TX 77008

33aNPI1881034064assigned 07/02/2013

33bProvider typeClinical Medical Laboratory

28Total paid$9.22M

24GClaims369,866

24DCodes billed6

24AFirst – last monthApr 2020 – Dec 2024

Compared with peers

Next to other Clinical Medical Laboratory providers in Texas

Rank by total paid#17 of 436

Median peer was paid$17K

This provider vs. median535×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2020	19,752	$1.12M
2021	133,187	$3.66M
2022	157,648	$3.26M
2023	51,013	$1.12M
2024incomplete	8,266	$62K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	74%	147,716	87,374	$6.78M
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	17%	116,050	71,328	$1.60M
87636	Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B	6.4%	23,726	11,167	$591K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	1.6%	3,936	3,637	$146K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	<1%	41,153	17,942	$90K
P9604	Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge	<1%	37,285	13,729	$9K

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialJENKINS, KELLY (VICE PRESIDENT)

Same official

Other billing entities under JENKINS, KELLY

Full network →

Provider	Location	Paid
Clearwater R-1 School District	Piedmont, MO	$65K

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.